{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:34:59Z","timestamp":1777880099007,"version":"3.51.4"},"reference-count":62,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["EDCTP2 RIA2017T-2018 WANECAM2"],"award-info":[{"award-number":["EDCTP2 RIA2017T-2018 WANECAM2"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The emergence and spread of antimalarial drug resistance have created an urgent need for novel therapeutic agents. Imidazolopiperazines (IZPs) represent a promising new class of compounds with broad activity against multiple stages of the malaria parasite life cycle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This scoping review aimed to map current evidence on the efficacy, mechanisms of action, resistance determinants, and clinical development of IZPs, particularly KAF156 (Ganaplacide) and its analog GNF179, to assess their potential as next-generation antimalarial agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria:<\/jats:title>\n                    <jats:p>\n                      Peer-reviewed studies of clinical,\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      , or\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      were included if they investigated IZPs for antimalarial efficacy, mechanisms of action or resistance, safety, or comparison with other drugs. Only English-language publications were considered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sources of evidence:<\/jats:title>\n                    <jats:p>Searches were performed in PubMed, Google Scholar, ClinicalTrials.gov, and organizational databases (MMV and Novartis). Citation mapping using Litmaps identified additional related studies. The final search was completed on December 20, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Charting methods:<\/jats:title>\n                    <jats:p>Two reviewers independently screened, selected, and extracted data using a form capturing study characteristics, compounds, parasite stages, efficacy, mechanisms of action or resistance, and safety. Discrepancies were resolved by consensus. Data were synthesized descriptively and summarized by study type, parasite stage, compound, and outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      IZPs demonstrate potent activity against asexual blood stages, liver stages, and gametocytes. Proposed mechanisms of action include mitochondrial disruption, sodium pump inhibition, and interference with protein trafficking. Resistance-associated mutations have been identified in genes such as\n                      <jats:italic toggle=\"yes\">Pfugt<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Pfact<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">Pfcarl<\/jats:italic>\n                      . Clinical trials of KAF156, including combination therapy with lumefantrine, report favorable efficacy, safety, and tolerability, with side effects that are generally mild and manageable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IZPs hold strong potential as next-generation antimalarial agents, particularly for combination therapies. Future research should prioritize clarifying mechanisms of action, monitoring resistance pathways, and optimizing clinical deployment strategies to address the ongoing challenges of antimalarial drug resistance and support malaria elimination goals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361251401771","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T09:47:41Z","timestamp":1766483261000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Imidazolopiperazines as next-generation antimalarial agents: a scoping review of efficacy, mechanisms of action and resistance; prospects for future development"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-2307","authenticated-orcid":false,"given":"Fatoumata Ousmane","family":"Maiga","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Point G. PBE: 1805, Bamako, Mali"},{"name":"Pathogens Genomics Diversity Network Africa, Imm Gwancoura, Sotuba, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-8439","authenticated-orcid":false,"given":"Laurent","family":"Dembele","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Point G. PBE: 1805, Bamako, Mali"},{"name":"Pathogens Genomics Diversity Network Africa, Imm Gwancoura, Sotuba, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Maiga","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdoulaye A.","family":"Djimde","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, Mali"},{"name":"Pathogens Genomics Diversity Network Africa, Imm Gwancoura, Sotuba, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0805011"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.76519"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuw037"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808859"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101746"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2404.170141"},{"key":"e_1_3_4_9_2","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 3rd ed. World Health Organization https:\/\/books.google.ml\/books?hl=en&lr=&id=IVo0DgAAQBAJ&oi=fnd&pg=PP1&ots=9Vne2pO7gJ&sig=uXiN-BEpAhCKPx6W2_4UZZo0E0E&redir_esc=y#v=onepage&q&f=false (2015 accessed 7 September 2025)."},{"key":"e_1_3_4_10_2","unstructured":"World Health Organization. A new malaria framework for Africa https:\/\/www.who.int\/news\/item\/23-08-2016-a-new-malaria-framework-for-africa (2016 accessed 7 September 2025)."},{"key":"e_1_3_4_11_2","unstructured":"World Health Organization. Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide https:\/\/iris.who.int\/bitstream\/handle\/10665\/379576\/9789240103603-eng.pdf?sequence=1 (2024 accessed 7 September 2025)."},{"key":"e_1_3_4_12_2","unstructured":"World Health Organization. World malaria report 2020: 20 years of global progress and challenges. Annual Report CC BY-NC-SA 3.0 IGO. https:\/\/www.who.int\/docs\/default-source\/malaria\/world-malaria-reports\/9789240015791-double-page-view.pdf?sfvrsn%20=%202c24349d_5 (2020 accessed 7 September 2025)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3347\/PHD.24053"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03987-6"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01234-19"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0477"},{"key":"e_1_3_4_17_2","first-page":"155","article-title":"A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa","volume":"16","author":"Ndwiga L","year":"2021","unstructured":"Ndwiga L, Kimenyi KM, Wamae K, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol 2021; 16: 155\u2013161.","journal-title":"Int J Parasitol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-19"},{"key":"e_1_3_4_19_2","unstructured":"World Health Organization. Malaria: artemisinin partial resistance https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/artemisinin-resistance (2022 accessed 18 March 2024)."},{"key":"e_1_3_4_20_2","unstructured":"World Health Organization. Strategy to respond to antimalarial drug resistance in Africa https:\/\/www.who.int\/publications-detail-redirect\/9789240060265 (2022 accessed 18 March 2024)."},{"key":"e_1_3_4_21_2","unstructured":"World Health Organization. World malaria report 2023 https:\/\/www.who.Int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023 (2023 accessed 13 October 2024)."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4103\/jpp.JPP_23_20"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00209-8"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602250"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1524871"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02727-13"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03478-14"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-2162-8"},{"key":"e_1_3_4_29_2","article-title":"Safety, pharmacokinetics, and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study","volume":"73","author":"Kublin JG","year":"2020","unstructured":"Kublin JG, Murphy SC, Maenza J, et al. Safety, pharmacokinetics, and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study. Clin Infect Dis 2020; 73: e2407\u2013e2414.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6138"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02235-17"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04916-22"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab133"},{"key":"e_1_3_4_34_2","article-title":"Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action","author":"Winzeler E","year":"2024","unstructured":"Winzeler E, Carolino K, De Souza ML, et al. Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action. Res Sq 2024; rs.3.rs-4892449.","journal-title":"Res Sq"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15440-4"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00466-24"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae300"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm2003359"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2941-5"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00696-16"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm300041e"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1931861"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S307113"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020838"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2724-z"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182013000747"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1211936"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01001-22"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml500244m"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes14122124"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.4c00563"},{"key":"e_1_3_4_52_2","article-title":"Assessment in vitro of the antimalarial and transmission-blocking activities of cipargamin and ganaplacide in artemisinin-resistant","volume":"66","author":"Yipsirimetee A","year":"2022","unstructured":"Yipsirimetee A, Chiewpoo P, Tripura R, et al. Assessment in vitro of the antimalarial and transmission-blocking activities of cipargamin and ganaplacide in artemisinin-resistant Plasmodium falciparum. Antimicrob Agents Chemother 2022; 66: e01481-21.","journal-title":"Plasmodium falciparum. Antimicrob Agents Chemother"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.166"},{"key":"e_1_3_4_54_2","unstructured":"Novartis. Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide\/lumefantrine-SDF combination in adults and children with malaria. Novartis https:\/\/www.novartis.com\/news\/media-releases\/novartis-and-medicines-malaria-venture-announce-decision-move-phase-3-study-novel-ganaplacidelumefantrine-sdf-combination-adults-and-children-malaria (2022 accessed 4 September 2025)."},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S279433"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00025"},{"key":"e_1_3_4_57_2","unstructured":"Hughes D. KAF\/lumefantrine. Medicines for malaria venture https:\/\/www.mmv.org\/newsroom\/news-resources-search\/kaflumefantrine (2018 accessed 14 March 2024)."},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.18.209973"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.877907"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.159047"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2008.06235.x"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.04.051"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182021002134"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251401771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361251401771","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251401771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:01:58Z","timestamp":1777593718000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361251401771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"alternative-id":["10.1177\/20499361251401771"],"URL":"https:\/\/doi.org\/10.1177\/20499361251401771","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"20499361251401771"}}